Unlearn, an innovative AI company, has recently succeeded in securing $50m in a Series C funding round led by Altimeter Capital, with the aim of advancing clinical research through digital twin technology. This significant funding round saw the involvement of several returning investors, including Wittington Ventures, Radical Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital, all of which have consistently supported Unlearn’s mission. Insight Partners, 8VC, DCVC, and DCVC Bio also joined as investors, further endorsing the company’s approach to revolutionising clinical trials.
With this newly acquired investment, Unlearn is poised to advance its mission of using AI to reduce trial and error in medicine. This will involve a focus on enhancing its workforce, data, engineering expertise, and research and development approaches. Since its establishment in 2017, Unlearn has secured over $130m for developing groundbreaking AI solutions, with the goal of creating digital twins for trial participants to lead to smaller and faster studies.
The company’s innovative technology has been designed to address the challenges that plague clinical research, such as prolonged timelines, slow enrolment, and patient reluctance due to the potential of receiving a placebo. Unlearn’s AI models work by generating a digital twin for each participant before they are randomised into the trial’s experimental or control arm. These digital twins forecast health outcomes under a placebo, irrespective of the actual therapy assignment, allowing for highly powered trials with smaller control groups, known as TwinRCTs.
Moreover, TwinRCTs enable more patients to receive experimental treatments, ultimately reducing the time needed to bring new drugs and therapies to the market. It is important to note that Unlearn has been actively collaborating with regulatory experts and has achieved a qualification from the European Medicines Agency for use in Phase II and III clinical trials with continuous outcomes. Additionally, the US Food and Drug Administration has confirmed that Unlearn’s methodology aligns with current guidance.
Charles Fisher, the founder and CEO of Unlearn, expressed his enthusiasm about the recent funding, stating, “Pharmaceutical companies are spending over $100bn a year on clinical research, yet the industry remains skeptical about new technology that has the power to truly transform research. Breaking down these barriers and proving the value of digital twin technology continues to be a main driver for us at Unlearn. And, this round of financing will allow us to not only grow our team but also expand our capabilities into more therapeutic areas to build awareness and prove the value.”
Prior to this, in April 2022, Unlearn secured $50m in a Series B financing round led by US-based global venture capital and private equity firm Insight Partners. This attests to the continual investor confidence in Unlearn’s pioneering approach to clinical research.
In conclusion, Unlearn’s recent funding success is a testament to the growing recognition and support for digital twin technology within the healthcare and pharmaceutical sector. With this substantial investment, the company is well-positioned to drive forward its mission of transforming the landscape of clinical trials and revolutionising the future of medicine.
+ There are no comments
Add yours